



<b>Acronym</b>	GARPEC
<b>Name</b>	Global Antibiotic Resistance, Prescribing, and Efficacy among neonates and Children
<b>ESPID contacts</b>	Julia Bielicki/ Mike Sharland
<b>For more information</b>	Rebecca Lundin <a href="mailto:rebecca.lundin@pentafoundation.org">rebecca.lundin@pentafoundation.org</a>
<b>Website</b>	<a href="http://www.garpec.org">www.garpec.org</a>

There is a lack of high quality, standardized data on AB use and AMR in neonates and children worldwide. This limits ability to develop sustainable and widely applicable strategies for

- Minimizing selection of AMR
- Defining effective antibiotic treatment approaches
- Instituting infection control measures.

**GARPEC aims to characterize antimicrobial prescription rates** among neonatal and pediatric patients using periodic point prevalence surveys **and to assess bloodstream infection (BSI) burden and resistance patterns** among neonatal and pediatric patients using routinely collected laboratory data.

GARPEC's aims will be achieved by

- Designing, evaluating and implementing customized web-based tools for surveillance activities
- Providing training and support in using these data entry tools
- Establishing a secure central repository for all anonymized data
- Providing a platform for future collaborative research.

A pilot of GARPEC activities will take place in the spring of 2015 in a number of selected centres across 6 continents.